Bayer HealthCare to License Accelrys Software.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Accelrys, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :ACCL ACCL American Canadian Caribbean Line ACCL Acceleration ACCL American College of Construction Lawyers ACCL Accreditation Council for Clinical Lipidology (Allied Health Certification Program) ACCL Amway China Co Limited ) today announced an agreement with Bayer Healthcare AG under which Bayer has licensed a comprehensive library of life science modeling software from Accelrys. These tools, which will be applied at Bayer's research centers in Germany and the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. , allow scientists to gain deeper insight into key issues in drug discovery and development, informing and accelerating their research. "The breadth of the Accelrys solutions was of particular interest to us," comments Dr. Alexander Hillisch, head of computational chemistry Computational chemistry is a branch of chemistry that uses computers to assist in solving chemical problems. It uses the results of theoretical chemistry, incorporated into efficient computer programs, to calculate the structures and properties of molecules and solids. at Bayer HealthCare AG. "As well as providing drug design tools such as pharmacophore pharmacophore the group of atoms in the molecule of a drug responsible for the drug's action. modeling and structure-based design, Accelrys offers quantum mechanical software that allows us to study reaction chemistry and predict chemical structure and properties with high accuracy. An example is the VAMP code, which we are applying to characterize our compound library." VAMP is a semi-empirical molecular orbital In chemistry, a molecular orbital is a region in which an electron may be found in a molecule.[1] MOs are introduced in qualitative and pictorial models of bonding in molecules, and specify the spatial distribution and energy of one (or a pair) of electrons. package capable of rapidly calculating many physical and chemical molecular properties. "We are delighted to be working with Bayer Healthcare," says Dr. Scott Kahn, chief science officer at Accelrys. "The agreement is a good example of the benefits of technology-transfer across the diverse scientific disciplines often required to be successful in research. In this case, Bayer is able to complement conventional life science modeling tools with a technology originally applied in materials and chemicals research and development." About Bayer HealthCare AG Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately 8.9 billion Euros in 2003, is one of the world's leading, innovative companies in the health care and medical products industry. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diagnostics and Pharmaceuticals. 34,600 people are employed by Bayer HealthCare worldwide. Our aim is to discover and manufacture innovative products that will improve human and animal health worldwide. Our products enhance well-being and quality of life by diagnosing, preventing and treating disease. Further information on Bayer HealthCare AG can be found at http://www.bayerhealthcare.com/. About Accelrys, Inc. Accelrys, Inc. (NASDAQ:ACCL) is a leading provider of software for computation, simulation, and the management and mining of scientific data used by biologists, chemists and materials scientists, including nanotechnology researchers for product design as well as drug discovery and development. Accelrys technology and services are designed to meet the needs of today's leading research organizations. The company is headquartered in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. . For more information about Accelrys, visit its website at http://www.accelrys.com/. When used anywhere in this document, the words expects, believes, anticipates, estimates, and similar expressions are intended to identify forward-looking statements. Forward-looking statements herein may include statements addressing future financial and operating results of Accelrys. Accelrys has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence ob·so·les·cent adj. 1. Being in the process of passing out of use or usefulness; becoming obsolete. 2. Biology Gradually disappearing; imperfectly or only slightly developed. of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and subsequent reports on Form 10-Q Form 10-Q See 10-Q. . All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys disclaims any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion